Onset and Duration of Clinical Effect of IPX066 in Advanced Parkinson's Disease

被引：0
|
作者：
Ellenbogen, Aaron
Hauser, Robert A.
Modi, Nishit B.
Hsu, Ann
Khanna, Sarita
Gupta, Suneel
机构：
来源：
ANNALS OF NEUROLOGY | 2015年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S419
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 50 条
  • [41] Dosing Patterns During Conversion to IPX066, Extended-Release Carbidopa-Levodopa, from Other Carbidopa-Levodopa Formulations in Advanced Parkinson's Disease Patients
    Morgan, John
    Stacy, Mark
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    NEUROLOGY, 2016, 86
  • [42] Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease
    Mao, Zhongping Lily
    Modi, Nishit B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (08): : 974 - 982
  • [43] Comparison of IPX066, a Novel Extended-Release Oral Carbidopa-Levodopa Formulation, to Immediate-Release Carbidopa-Levodopa in Patients with Advanced Parkinson's Disease (PD)
    Hsu, Ann
    Metman, Leonard Verhagen
    Ellenbogen, Aaron
    O'Connell, Martin
    Modi, Nishit B.
    Kell, Sherron
    Gupta, Suneel
    NEUROLOGY, 2010, 74 (09) : A350 - A350
  • [44] PHARMACODYNAMICS OF IPX066, AN EXTENDED-RELEASE CAPSULE FORMULATION OF CARBIDOPA-LEVODOPA (CD-LD), IN PATIENTS WITH EARLY PARKINSON'S DISEASE: A DISEASE PROGRESSION MODEL
    Mao, Z.
    Hsu, A.
    Gupta, S.
    Modi, N. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S81 - S81
  • [45] Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease
    Tetrud, James
    Nausieda, Paul
    Kreitzman, David
    Liang, Grace S.
    Nieves, Anette
    Duker, Andrew P.
    Hauser, Robert A.
    Farbman, Eric S.
    Ellenbogen, Aaron
    Hsu, Ann
    Kell, Sherron
    Khanna, Sarita
    Rubens, Robert
    Gupta, Suneel
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 373 : 116 - 123
  • [46] Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial
    Waters, Cheryl H.
    Nausieda, Paul
    Dzyak, Lyudmila
    Spiegel, Joerg
    Rudzinska, Monika
    Silver, Dee E.
    Tsurkalenko, Elena S.
    Kell, Sherron
    Hsu, Ann
    Khanna, Sarita
    Gupta, Suneel
    CNS DRUGS, 2015, 29 (04) : 341 - 350
  • [47] Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
    Morgan, John C.
    Dhall, Rohit
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    PARKINSONS DISEASE, 2018, 2018
  • [48] Improvements in activities of daily living and quality of life measures in Hoehn & Yahr subgroups of advanced Parkinson's disease patients following treatment with IPX066, extended-release carbidopa-levodopa
    Dhall, Rohit
    Gil, Ramon
    Lindemulder, Elizabeth
    Rubens, Robert
    Gupta, Suneel
    NEUROLOGY, 2017, 88
  • [49] Comparison of IPX066, a Novel Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, and CD-LD-Entacapone (CLE) in Advanced Parkinson's Disease (ASCEND-PD Trial)
    Stocchi, Fabrizio
    Dillmann, Ulrich
    Ellenbogen, Aaron
    Hsu, Ann
    Khanna, Sarita
    Rubens, Robert
    Liang, Grace
    Gupta, Suneel
    NEUROLOGY, 2012, 78
  • [50] Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease
    Hauser, Robert A.
    Ellenbogen, Aaron
    Khanna, Sarita
    Gupta, Suneel
    Modi, Nishit B.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 839 - 845
12345